Key findings from the Phase 2 trial included: Dose-dependent weight loss , with greater reductions observed at higher doses Significant improvements in waist circumference , blood pressure , and lipid profiles Reductions in fasting glucose and insulin resistance markers, though the clinical significance of these findings in people with type 2 diabetes requires further investigation Weight loss appeared to continue throughout the 48-week period without a clear plateau at the highest doses Whilst these results are encouraging, it is important to contextualise them appropriately
doi: 10.1038/cr.2011.22
Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), is a chronic condition characterized by a range of persistent symptoms that last for weeks or months following the initial COVID-19 infection, affecting multiple organ systems and significantly impairing daily functioning and quality of life
Comparative incretin pharmacology pairing tirzepatide against semaglutide (single GLP-1 agonist) and retatrutide (triple GLP-1, GIP, glucagon agonist) to map the contribution of each incretin receptor in cell-culture and animal models
doi: 10.3390/nu13103432
Boxcar scars are wide depressions with sharply defined edges, while ice pick scars are deep, narrow scars
